Janssen’s Balversa gets FDA approval for metastatic bladder cancer
Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration
Balversa is now indicated in the US for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration
The investment in AskBio includes an amount of $225m committed by global alternative asset firm TPG Capital and life sciences investment firm Vida Ventures in exchange of a
Wockhardt’s Decitabine Injection is a generic version of Dacogen, marketed in USA and other countries by Otsuka. Decitabine is used to treat Myelodysplastic syndromes (MDS), a group of
The trial, called DIAMOND, is the first prospective phase 3 trial which is assessing the rapid initiation of a single-tablet regimen (STR) SYMTUZA for the treatment of human
The study will be conducted at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta. “Given the exciting data Emory University researchers presented at the
The latest approval for Lynparza in Europe is for its use as a monotherapy for adult patients with germline BRCA1/2-mutations (gBRCAm), and who have human epidermal growth factor
Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimin’s efficacy and safety
Delivering an inhaled Dry Powder formulation of Aspirin directly into the deep sites of the lung is a novel new approach to lung cancer treatment. This new treatment
Under the terms of the partnership, South Korea-based Celltrion will undertake manufacturing and supply of four recombinant antibodies to iProgen. Among the four antibodies, two will be targeting
INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the U.S. Food and Drug Administration (FDA) in July 2018 in combination with